CADL:NSD-Candel Therapeutics Inc. Common Stock (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.13

Change

-0.39 (-11.08)%

Market Cap

USD 0.10B

Volume

0.09M

Avg Analyst Target

USD 12.00 (+283.39%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Candel Therapeutics Inc. Common Stock (CADL) Stock Analysis:
Based on the Candel Therapeutics Inc. Common Stock stock forecasts from 1 analysts, the average analyst target price for Candel Therapeutics Inc. Common Stock is USD 12.00 over the next 12 months. Candel Therapeutics Inc. Common Stock’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Candel Therapeutics Inc. Common Stock is Slightly Bearish, which is based on 1 positive signals and 2 negative signals. At the last closing, Candel Therapeutics Inc. Common Stock’s stock price was USD 3.13. Candel Therapeutics Inc. Common Stock’s stock price has changed by -21.75% over the past week, -35.86% over the past month and 0% over the last year.

About

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
GILD Gilead Sciences Inc

+0.69 (+1.08%)

USD80.08B 17.83 11.21
REGN Regeneron Pharmaceuticals Inc

+4.11 (+0.60%)

USD72.62B 9.40 7.18
VRTX Vertex Pharmaceuticals Incorpo..

+0.13 (+0.05%)

USD66.14B 27.29 19.22
MRNA Moderna Inc

-5.56 (-4.04%)

USD54.19B 4.01 2.75
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

-8.72 (-5.34%)

USD39.61B 3.12 1.86
RPRX Royalty Pharma plc

-0.31 (-0.77%)

USD26.64B 28.87 15.23
SGEN Seagen Inc

-5.87 (-4.21%)

USD25.70B 55.02 44.86
GMAB Genmab A/S

-0.30 (-0.97%)

USD20.43B 60.76 5.35
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CADL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -59.97% 29% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.97% 29% F 18% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.10B 45% F 29% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.67 52% F 49% F
Price / Cash Flow Ratio -4.53 65% D 70% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -76.23% 37% F 16% F
Return on Invested Capital -122.27% 16% F 9% F
Return on Assets -26.99% 47% F 15% F
Debt to Equity Ratio 0.87% 84% B 87% B+
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.55 89% B+ 83% B
Short Percent 0.29% 94% A 86% B
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.